We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod
Read MoreHide Full Article
Merck (MRK - Free Report) announced that the FDA has granted approval to its and its Germany-based partner Bayer’s (BAYRY - Free Report) vericiguat, a soluble guanylate cyclase (sGC) stimulator, to treat patients with worsening chronic heart failure with reduced ejection fraction (HFrEF).
Vericiguat will be marketed by the brand name of Verquvo to reduce the risk of cardiovascular death and heart failure hospitalization, following hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.
However, the approval comes with a boxed warning that indicates that the drug should not be given to pregnant ladies because it may cause fetal harm.
In the past year, Merck’s shares have declined 8.3% against an increase of 6.1% for the industry.
The FDA approval for the candidate was based on data from the phase III VICTORIA study. The VICTORIA study evaluated vericiguat versus placebo when given in combination with available heart failure therapies in patients with symptomatic chronic heart failure and ejection fraction less than 45% following a worsening heart failure event.
Data from the study showed that vericiguat was superior to placebo in reducing the risk of composite endpoint of heart failure hospitalization or cardiovascular death in such patients. The data showed that there was a 4.2% reduction in annualized absolute risk with Verquvo compared with placebo. Verquvo tablets (2.5 mg, 5 mg, and 10 mg) have been jointly developed by Bayer and Merck.
Novartis’ (NVS - Free Report) Entresto is approved to treat HFrEF. However, Verquvo is the first treatment for chronic heart failure approved specifically for patients following hospitalization for heart failure or need for outpatient IV diuretics.
Cytokinetics’ pipeline candidate, omecamtiv mecarbil is in late-stage development for HFrEF. Cytokinetics was earlier developing omecamtiv mecarbil with Amgen (AMGN - Free Report) . However, in November last year, Amgen transitioned development and commercialization rights to omecamtiv mecarbil to Cytokinetics.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod
Merck (MRK - Free Report) announced that the FDA has granted approval to its and its Germany-based partner Bayer’s (BAYRY - Free Report) vericiguat, a soluble guanylate cyclase (sGC) stimulator, to treat patients with worsening chronic heart failure with reduced ejection fraction (HFrEF).
Vericiguat will be marketed by the brand name of Verquvo to reduce the risk of cardiovascular death and heart failure hospitalization, following hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.
However, the approval comes with a boxed warning that indicates that the drug should not be given to pregnant ladies because it may cause fetal harm.
In the past year, Merck’s shares have declined 8.3% against an increase of 6.1% for the industry.
The FDA approval for the candidate was based on data from the phase III VICTORIA study. The VICTORIA study evaluated vericiguat versus placebo when given in combination with available heart failure therapies in patients with symptomatic chronic heart failure and ejection fraction less than 45% following a worsening heart failure event.
Data from the study showed that vericiguat was superior to placebo in reducing the risk of composite endpoint of heart failure hospitalization or cardiovascular death in such patients. The data showed that there was a 4.2% reduction in annualized absolute risk with Verquvo compared with placebo. Verquvo tablets (2.5 mg, 5 mg, and 10 mg) have been jointly developed by Bayer and Merck.
Novartis’ (NVS - Free Report) Entresto is approved to treat HFrEF. However, Verquvo is the first treatment for chronic heart failure approved specifically for patients following hospitalization for heart failure or need for outpatient IV diuretics.
Cytokinetics’ pipeline candidate, omecamtiv mecarbil is in late-stage development for HFrEF. Cytokinetics was earlier developing omecamtiv mecarbil with Amgen (AMGN - Free Report) . However, in November last year, Amgen transitioned development and commercialization rights to omecamtiv mecarbil to Cytokinetics.
Merck currently carries a Zacks Rank #2 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>